| First Author | Patel S | Year | 2019 |
| Journal | FASEB J | Volume | 33 |
| Issue | 9 | Pages | 9797-9810 |
| PubMed ID | 31095421 | Mgi Jnum | J:293970 |
| Mgi Id | MGI:6452658 | Doi | 10.1096/fj.201802489RR |
| Citation | Patel S, et al. (2019) Rac-GTPase promotes fibrotic TGF-beta1 signaling and chronic kidney disease via EGFR, p53, and Hippo/YAP/TAZ pathways. FASEB J 33(9):9797-9810 |
| abstractText | Rac-GTPases are major regulators of cytoskeletal remodeling and their deregulation contributes to numerous pathologies. Whether or how Rac promotes tubulointerstitial fibrosis and chronic kidney disease (CKD) is currently unknown. We showed that the major profibrotic cytokine, TGF-beta1 promoted rapid Rac1-GTP loading in human kidney 2 (HK-2) human renal epithelial cells. A Rac-specific chemical inhibitor, EHT 1864, blocked TGF-beta1-induced fibrotic reprogramming in kidney epithelial cells and fibroblasts. Stable Rac1 depletion in HK-2 cells, moreover, eliminated TGF-beta1-mediated non-SMAD pathway activation [e.g., Src, epidermal growth factor receptor (EGFR), p53] and subsequent plasminogen activator inhibitor-1 (PAI-1), connective tissue growth factor, fibronectin, and p21 induction. Rac1 and p22(phox) knockdown abrogated free radical generation by TGF-beta1 in HK-2 cells, consistent with the role of Rac1 in NAPD(H). TGF-beta1-induced renal epithelial cytostasis was also completely bypassed by Rac1, p22(phox), p47(phox), and PAI-1 silencing. Rac1b isoform expression was robustly induced in the fibrotic kidneys of mice and humans. Intraperitoneal administration of EHT 1864 in mice dramatically attenuated ureteral unilateral obstruction-driven EGFR, p53, Rac1b, yes-associated protein/transcriptional coactivator with PDZ-binding motif activation/expression, dedifferentiation, cell cycle arrest, and renal fibrogenesis evident in vehicle-treated obstructed kidneys. Thus, the Rac1-directed redox response is critical for TGF-beta1-driven epithelial dysfunction orchestrated, in part, via PAI-1 up-regulation. Rac pathway inhibition suppressed renal oxidative stress and maladaptive repair, identifying Rac as a novel therapeutic target against progressive CKD.-Patel, S., Tang, J., Overstreet, J. M., Anorga, S., Lian, F., Arnouk, A., Goldschmeding, R., Higgins, P. J., Samarakoon, R. Rac-GTPase promotes fibrotic TGF-beta1 signaling and chronic kidney disease via EGFR, p53, and Hippo/YAP/TAZ pathways. |
